scholarly journals Autoimmune Hepatitis: Treatment Options and Management Review

Cureus ◽  
2021 ◽  
Author(s):  
Eyad Gadour
Keyword(s):  
Autoimmune Hepatitis ◽  
Treatment Options ◽  
Management Review ◽  
Hepatitis Treatment

A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment

2018 ◽  
Vol 30 (2) ◽  
pp. 212-216 ◽  
Author(s):  
Michele De Lemos-Bonotto ◽  
Cristiane Valle-Tovo ◽  
Ane M. Costabeber ◽  
Angelo A. Mattos ◽  
André L.F. Azeredo-da-Silva
Keyword(s):  
Systematic Review ◽  
Autoimmune Hepatitis ◽  
Meta Analysis ◽  
Second Line ◽  
Hepatitis Treatment

scholarly journals SUN-508 Dissociation of Clinical Course of Coexisting Autoimmune Hepatitis and Graves Disease

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Aesha Patel ◽  
Camille Stanback ◽  
Priyathama Vellanki
Keyword(s):  
Autoimmune Hepatitis ◽  
Total Bilirubin ◽  
Liver Enzymes ◽  
Clinical Course ◽  
Graves Disease ◽  
Free T4 ◽  
Lower Extremity Weakness ◽  
Hepatitis Treatment ◽  
Definitive Therapy ◽  
Initial Improvement

Abstract Title: Dissociation of Clinical Course of Coexisting Autoimmune Hepatitis and Graves Disease Introduction: The association between Graves’ disease and coexisting autoimmune hepatitis is well known. Treatment of autoimmune hepatitis with glucocorticoids can concurrently lower thyroid hormone levels. Additionally, recurrence of hyperthyroidism has been shown to be associated with recurrence of autoimmune hepatitis. We present a case of a patient with autoimmune hepatitis and Graves’ thyrotoxicosis, which initially improved with prednisone therapy, but thyrotoxicosis recurred during the prednisone taper while hepatitis stayed in remission. Clinical Case: A 47-year old female initially presented with fatigue, nausea, and jaundice. Liver enzymes showed elevated AST (1634 U/L) and ALT (1956 U/L) with total bilirubin 15.1 mg/dL. Liver biopsy was consistent with autoimmune hepatitis. Treatment was initiated with ursodiol 300 mg TID and liver enzymes improved to ALT 579 IU/L and AST 544 IU/L with total bilirubin 1.9 mg/dL. Nine months later, she presented with worsening upper and lower extremity weakness, slurred speech, abdominal pain, and nausea and vomiting. AST and ALT were again elevated to >1,000 U/L. TFTs were checked due to symptoms of palpitations and heat intolerance. TSH was 0.024 uIU/mL with elevated free T4 of 3.74 ng/dL and TSI of 435%. She was treated with prednisone, cholestyramine, and propranolol and discharged with a one-month prednisone taper starting at 60 mg daily. LFTs and TFTs normalized after one month. Cholestyramine was discontinued and prednisone was tapered to 5 mg daily. Seven months later, she had symptoms of palpitations and heat intolerance. TFTs were consistent with hyperthyroidism (TSH 0.049 uIU/mL, free T4 3.96 ng/dL). LFTs remained in normal range. Since thionamides have relative contraindications in patients with liver disease, prednisone was increased from 5 mg to 20 mg daily and cholestyramine was resumed to treat hyperthyroidism. After five months, TSH remained suppressed to 0.019 uIU/mL however free T4 improved to 1.74 ng/dL. The patient was referred for total thyroidectomy. Conclusion: This case illustrates an example of the rarely reported occurrence of thyrotoxicosis recrudescence despite initial improvement with treatment of underlying autoimmune hepatitis. Recognition of recurrence of hyperthyroidism independent of recurrence of autoimmune hepatitis indicates the need for early definitive therapy for hyperthyroidism.

scholarly journals Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials

2010 ◽  
Vol 53 (1) ◽  
pp. 191-198 ◽  
Author(s):  
Mieke M.H. Lamers ◽  
Martijn G.H. van Oijen ◽  
Martine Pronk ◽  
Joost P.H. Drenth
Keyword(s):  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Treatment Options ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Ethmoiditis during Autoimmune Hepatitis Treatment: A Case Report

2020 ◽  
Vol 04 (04) ◽  
Author(s):  
Elia C ◽  
Boano V ◽  
Battaglia E ◽  
Grassini M
Keyword(s):  
Case Report ◽  
Autoimmune Hepatitis ◽  
Hepatitis Treatment

scholarly journals Autoimmune hepatitis treatment in the elderly: A systematic review

2019 ◽  
Vol 25 (22) ◽  
pp. 2809-2818
Author(s):  
Marilena Durazzo ◽  
Giulia Lupi ◽  
Michela Scandella ◽  
Arianna Ferro ◽  
Gabriella Gruden
Keyword(s):  
Systematic Review ◽  
Autoimmune Hepatitis ◽  
The Elderly ◽  
Hepatitis Treatment

scholarly journals Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance

2018 ◽  
Vol 6 (4) ◽  
pp. 284-290
Author(s):  
John Guirguis ◽  
Yilien Alonso ◽  
Rocio Lopez ◽  
William Carey
Keyword(s):  
Liver Biopsy ◽  
Autoimmune Hepatitis ◽  
Treatment Withdrawal ◽  
Hepatitis Treatment

The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases

2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum
Keyword(s):  
Rare Diseases ◽  
Treatment Options ◽  
Castleman Disease ◽  
High Impact ◽  
Collaborative Network ◽  
Network Approach ◽  
Grant Applications ◽  
Research Questions ◽  
Novel Strategy ◽  
Patient Centric

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.

Sign in / Sign up

Export Citation Format

Share Document